These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 30965037)

  • 1. Allogeneic hematopoietic stem cell transplant outcomes for patients with dominant negative IKZF1/IKAROS mutations.
    Kellner ES; Krupski C; Kuehn HS; Rosenzweig SD; Yoshida N; Kojima S; Boutboul D; Latour S; Barlogis V; Galambrun C; Stray-Pedersen A; Erichsen HC; Marsh RA
    J Allergy Clin Immunol; 2019 Jul; 144(1):339-342. PubMed ID: 30965037
    [No Abstract]   [Full Text] [Related]  

  • 2. Ikaros family zinc-finger 1 mutation is an independent factor for the poor prognosis of adult B-cell acute lymphoblastic leukemia, and allogeneic hematopoietic stem cell transplantation can improve clinical outcomes.
    Tang S; Shen H; Qu C; Dai H; Zhu X; Xue S; Ding Z; Lu J; Wu D; Tang X
    Bone Marrow Transplant; 2019 Feb; 54(2):236-243. PubMed ID: 29942002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IKAROS gain of function disease: Allogeneic hematopoietic cell transplantation experience and expanded clinical phenotypes.
    Klangkalya N; Stoddard J; Niemela J; Sponaugle J; Greenwell IB; Reigh E; Kuehn HS; Kanakry JA; Rosenzweig SD; Dimitrova D
    Clin Immunol; 2024 Mar; 260():109922. PubMed ID: 38320737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dominant-negative IKZF1 mutations cause a T, B, and myeloid cell combined immunodeficiency.
    Boutboul D; Kuehn HS; Van de Wyngaert Z; Niemela JE; Callebaut I; Stoddard J; Lenoir C; Barlogis V; Farnarier C; Vely F; Yoshida N; Kojima S; Kanegane H; Hoshino A; Hauck F; Lhermitte L; Asnafi V; Roehrs P; Chen S; Verbsky JW; Calvo KR; Husami A; Zhang K; Roberts J; Amrol D; Sleaseman J; Hsu AP; Holland SM; Marsh R; Fischer A; Fleisher TA; Picard C; Latour S; Rosenzweig SD
    J Clin Invest; 2018 Jul; 128(7):3071-3087. PubMed ID: 29889099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Common Variable Immunodeficiency, Autoimmune Hemolytic Anemia, and Pancytopenia Associated With a Defect in IKAROS.
    Yilmaz E; Kuehn HS; Odakir E; Niemela JE; Ozcan A; Eken A; Rohlfs M; Cansever M; Gok V; Aydin F; Karakukcu M; Hauck F; Klein C; Unal E; Rosenzweig SD; Patiroglu T
    J Pediatr Hematol Oncol; 2021 Apr; 43(3):e351-e357. PubMed ID: 33122583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective randomized trial comparing cyclosporine/methotrexate and tacrolimus/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation.
    Törlén J; Ringdén O; Garming-Legert K; Ljungman P; Winiarski J; Remes K; Itälä-Remes M; Remberger M; Mattsson J
    Haematologica; 2016 Nov; 101(11):1417-1425. PubMed ID: 27662016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical features of late onset non-infectious pulmonary complications following pediatric allogeneic hematopoietic stem cell transplantation.
    Park M; Koh KN; Kim BE; Im HJ; Seo JJ
    Clin Transplant; 2011; 25(2):E168-76. PubMed ID: 21077955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IKZF1 (IKAROS) deletions in B-ALL and its clinical correlation: A prospective study from a tertiary care centre in Northern India.
    Gupta SK; Bakhshi S; Kumar L; Seth R; Kumar R
    Leuk Res; 2016 Feb; 41():7-11. PubMed ID: 26704074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diffuse alveolar hemorrhage is most often fatal and is affected by graft source, conditioning regimen toxicity, and engraftment kinetics.
    Keklik F; Alrawi EB; Cao Q; Bejanyan N; Rashidi A; Lazaryan A; Arndt P; Dincer EH; Bachanova V; Warlick ED; MacMillan ML; Arora M; Miller J; Brunstein CG; Weisdorf DJ; Ustun C
    Haematologica; 2018 Dec; 103(12):2109-2115. PubMed ID: 30076172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ikaros (IKZF1) alterations and minimal residual disease at day 15 assessed by flow cytometry predict prognosis of childhood BCR/ABL-negative acute lymphoblastic leukemia.
    Volejnikova J; Mejstrikova E; Dörge P; Meissner B; Zimmermannova O; Svojgr K; Stanulla M; Cario G; Schrappe M; Stary J; Hrusak O; Trka J; Fronkova E
    Pediatr Blood Cancer; 2013 Mar; 60(3):420-7. PubMed ID: 22997141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recipient interferon-gamma 3/3 genotype contributes to the development of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Bogunia-Kubik K; Mlynarczewska A; Wysoczanska B; Lange A
    Haematologica; 2005 Mar; 90(3):425-6. PubMed ID: 15749687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Germline
    Kuehn HS; Nunes-Santos CJ; Rosenzweig SD
    Expert Rev Clin Immunol; 2021 Apr; 17(4):407-416. PubMed ID: 33691560
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of acute graft-versus-host disease on the outcome of second allogeneic hematopoietic stem cell transplant in children.
    Schechter T; Avila L; Frangoul H; Domm J; Dupuis LL; Naithani R; Zhao X; Pollock-Barziv S; Roifman C; Gassas A; Doyle J
    Leuk Lymphoma; 2013 Jan; 54(1):105-9. PubMed ID: 22721498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic inactivation of Ikaros is a rare event in human T-ALL.
    Marçais A; Jeannet R; Hernandez L; Soulier J; Sigaux F; Chan S; Kastner P
    Leuk Res; 2010 Apr; 34(4):426-9. PubMed ID: 19796813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk Factors for Transplant Outcomes in Children and Adolescents with Non-Malignant Diseases Following Allogeneic Hematopoietic Stem Cell Transplantation.
    Zaucha-Prażmo A; Sadurska E; Pieczonka A; Goździk J; Dębski R; Drabko K; Zawitkowska J; Lejman M; Wachowiak J; Styczyński J; Kowalczyk JR
    Ann Transplant; 2019 Jun; 24():374-382. PubMed ID: 31235684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups.
    Inamoto Y; Kimura F; Kanda J; Sugita J; Ikegame K; Nakasone H; Nannya Y; Uchida N; Fukuda T; Yoshioka K; Ozawa Y; Kawano I; Atsuta Y; Kato K; Ichinohe T; Inoue M; Teshima T;
    Haematologica; 2016 Dec; 101(12):1592-1602. PubMed ID: 27662017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of unrelated cord blood transplants and allogeneic-related hematopoietic stem cell transplants in children with high-risk acute lymphocytic leukemia.
    Jacobsohn DA; Hewlett B; Ranalli M; Seshadri R; Duerst R; Kletzel M
    Bone Marrow Transplant; 2004 Nov; 34(10):901-7. PubMed ID: 15361908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The abnormal expression of IKZF1 encoded protein-IKAROS in B-ALL children].
    Huang XH; Chen J; Li BS
    Zhongguo Dang Dai Er Ke Za Zhi; 2013 Sep; 15(9):743-7. PubMed ID: 24034916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple functions of Ikaros in hematological malignancies, solid tumor and autoimmune diseases.
    Chen Q; Shi Y; Chen Y; Ji T; Li Y; Yu L
    Gene; 2019 Feb; 684():47-52. PubMed ID: 30352248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary graft failure after myeloablative allogeneic hematopoietic cell transplantation for hematologic malignancies.
    Olsson RF; Logan BR; Chaudhury S; Zhu X; Akpek G; Bolwell BJ; Bredeson CN; Dvorak CC; Gupta V; Ho VT; Lazarus HM; Marks DI; Ringdén OT; Pasquini MC; Schriber JR; Cooke KR
    Leukemia; 2015 Aug; 29(8):1754-62. PubMed ID: 25772027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.